Department of Chemistry , University at Buffalo, The State University of New York , Buffalo , New York 14260-3000 , United States.
Biochemistry. 2019 Dec 31;58(52):5234-5244. doi: 10.1021/acs.biochem.9b00293. Epub 2019 Apr 24.
Covalent inhibitors are experiencing a growing resurgence in drug design and are an increasingly useful tool in molecular biology. The ability to attach inhibitors to their targets by a covalent linkage offers pharmacodynamic and pharmacokinetic advantages, but this can also be a liability if undesired off-target reactions are not mitigated. The discovery of new electrophilic groups that react selectively with specific amino acid residues is therefore highly desirable in the design of targeted covalent inhibitors (TCIs). Additionally, the ability to control the reactivity through exploitation of the target enzyme's machinery, as in mechanism-based inhibitors (MBIs), greatly benefits from the discovery of new strategies. This Perspective showcases recent advances in electrophile development and their application in TCIs and MBIs, exhibiting high selectivity for their targets.
共价抑制剂在药物设计中经历了复兴,并且是分子生物学中越来越有用的工具。通过共价键将抑制剂连接到其靶标上的能力提供了药效学和药代动力学优势,但如果不能减轻不希望的非靶标反应,这也可能成为一种负担。因此,在设计靶向共价抑制剂 (TCI) 时,非常需要发现能够与特定氨基酸残基选择性反应的新的亲电基团。此外,通过利用靶酶的机制(如在基于机制的抑制剂 (MBI) 中)来控制反应性的能力,从新策略的发现中受益匪浅。本观点展示了亲电试剂开发的最新进展及其在 TCI 和 MBI 中的应用,对其靶标表现出高选择性。